• Syed Shahed Syed Rasheed
• Rajat Sayyed

EOE is a long-term immune-mediated condition causing esophageal dysfunction and inflammation. Treatment options include proton pump inhibitors and swallowed topical steroids. This study aims to develop an orodispersible film containing budesonide, a poorly soluble anti-inflammatory medication, based on limited trials. The solvent casting technique is used to formulate orodispersible film. Preliminary batches were prepared for the selection of polymers, and from the preliminary batches, HPMC E15 LV combined with PEG 400 as a plasticizer demonstrated outstanding in vitro disintegration time and cumulative percent dissolution. A 32 factorial design with three levels and two factors was used, with polymer (X1) and plasticizer (X2) as independent variables. Formulated films were evaluated for their appearance, thickness, weight variation, surface pH, folding endurance, disintegration time, and in vitro dissolution rate. After evaluating the various batches of films, the F5 batch achieved the desired results, releasing 98.82% of the medication in just 5 minutes, resulting in quick film dissolution.

Eosinophilic Esophagitis (EOE), Budesonide, HPMC E15, Solvent casting, Orodispersible film (ODF).

"FORMULATION AND EVALUATION OF BUDESONIDE ORODISPERSIBLE FILM FOR EOSINOPHILIC ESOPHAGITIS", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.10, Issue 8, page no.f457-f468, August-2023, Available :http://www.jetir.org/papers/JETIR2308553.pdf

"FORMULATION AND EVALUATION OF BUDESONIDE ORODISPERSIBLE FILM FOR EOSINOPHILIC ESOPHAGITIS", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.10, Issue 8, page no. ppf457-f468, August-2023, Available at : http://www.jetir.org/papers/JETIR2308553.pdf